Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

September 17, 2019

Primary Completion Date

August 22, 2023

Study Completion Date

August 22, 2023

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Treprostinil Inhalation Powder

Treprostinil inhalation powder single-use cartridges containing either 32 or 48 micrograms of treprostinil per cartridge (QID)

Trial Locations (16)

19104

Penn Medicine University City, Philadelphia

21201

University of Maryland Medical Center Division of Cardiology, Baltimore

23230

Pulmonary Associates of Richmond, Inc., Richmond

23507

Sentara Norfolk General Hospital, Norfolk

30322

Emory University Hospital, Atlanta

32204

Ascension / St. Vincent's Lung Institute, Jacksonville

32224

Mayo Clinic Florida, Jacksonville

33331

Cleveland Clinic Florida, Weston

33606

University of South Florida Center for Advanced Lung Disease, Tampa

35233

University of Alabama at Birmingham, Birmingham

40202

University of Louisville Clinical Trials Unit, Louisville

66160

The University of Kansas Medical Center, Kansas City

70121

Ochsner Medical Center, New Orleans

75390

UT Southwestern Medical Center, Dallas

77030

Houston Methodist Hospital, Houston

90073

Department of Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles

Sponsors
All Listed Sponsors
lead

United Therapeutics

INDUSTRY